<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04788368</url>
  </required_header>
  <id_info>
    <org_study_id>TRECA</org_study_id>
    <nct_id>NCT04788368</nct_id>
  </id_info>
  <brief_title>TRECA - TREatment of Colorectal Adenomas and Early Colorectal CAncer in Region Västra Götaland</brief_title>
  <acronym>TRECA</acronym>
  <official_title>TRECA - TREatment of Colorectal Adenomas and Early Colorectal CAncer in Region Västra Götaland</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      All early colorectal cancers (T1-T2) treated in the Region Västra Götaland from 2007-2020&#xD;
      will be evaluated. To establish the extent to which early colorectal cancers have been&#xD;
      treated with local excision? How have treatment strategies changed over time? The study will&#xD;
      provide information on where these patients have been treated in the Region Västra Götaland.&#xD;
      During the study period, ESD was introduced as a treatment modality, and it will investigated&#xD;
      how this may have influenced treatment strategies for complex adenomas. Clinical outcome&#xD;
      measures will include recurrence rates and re-intervention rates for the respective&#xD;
      treatments. Possible areas of improvement will be identified and determine if evidence based&#xD;
      and best practice guidelines are met with the current treatment strategies in Region Västra&#xD;
      Götaland.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>2 Months</target_duration>
  <primary_outcome>
    <measure>Pathological clear margins</measure>
    <time_frame>1-2 months after surgery</time_frame>
    <description>Pathological examination of the specimen showing free margins</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complications after surgery</measure>
    <time_frame>90 days after surgery</time_frame>
    <description>Complications graded using the Clavien Dindo classification</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Rectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Patients treated with TEM - transanala microsurgery</arm_group_label>
    <description>Early rectal cancer treated with TEM - full thickness resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients treated with ESD</arm_group_label>
    <description>Early rectal cancer treated with the endoscopic treatment ESD - endoscopic submucosal resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients treated with EMR</arm_group_label>
    <description>Early rectal cancer treated with the endoscopic treatment EMR - endoscopic mucosal resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical resection</intervention_name>
    <description>Surgical resection with either of the above mentioned techniques</description>
    <arm_group_label>Patients treated with EMR</arm_group_label>
    <arm_group_label>Patients treated with ESD</arm_group_label>
    <arm_group_label>Patients treated with TEM - transanala microsurgery</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with rectal cancer treated with a local resection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Rectal cancer resected by local resection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All other types of resection or treatment for rectal cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eva Angenete, MD. PhD</last_name>
    <phone>+46760514441</phone>
    <email>eva.angenete@vgregion.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eva Angenete</last_name>
    <phone>0760514441</phone>
    <email>eva.angenete@vgregion.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Rydbeck, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Eva Angenete</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

